SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001171843-19-007745
Filing Date
2019-11-22
Accepted
2019-11-22 14:35:26
Documents
13
Period of Report
2019-11-22
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_112219.htm   iXBRL 8-K 14725
  Complete submission text file 0001171843-19-007745.txt   216023

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE gnw-20190101.xsd EX-101.SCH 3095
3 XBRL DEFINITION FILE gnw-20190101_def.xml EX-101.DEF 25969
4 XBRL LABEL FILE gnw-20190101_lab.xml EX-101.LAB 35566
5 XBRL PRESENTATION FILE gnw-20190101_pre.xml EX-101.PRE 24600
13 EXTRACTED XBRL INSTANCE DOCUMENT f8k_112219_htm.xml XML 3064
Mailing Address 171 OYSTER POINT BLVD, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650741-7700
Global Blood Therapeutics, Inc. (Filer) CIK: 0001629137 (see all company filings)

IRS No.: 274825712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37539 | Film No.: 191240733
SIC: 2834 Pharmaceutical Preparations